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Abstract
Background: Preventive chemotherapy with albendazole or mebendazole is the current strategy to control soil-
transmitted helminth (STH) infections (i.e. Ascaris lumbricoides, hookworm and Trichuris trichiura). STH reinfections, in
particular A. lumbricoides and T. trichiura occur rapidly after treatment with the standard drugs. However, their low
efficacy against T. trichiura, made an accurate assessment of reinfection patterns impossible.
Methods: In 2013 a randomised controlled trial was conducted on Pemba Island, Tanzania. School-aged children
diagnosed positive for T. trichiura, were randomly allocated to (i) albendazole-ivermectin; (ii) albendazole-mebendazole;
(iii) albendazole-oxantel pamoate; or (iv) mebendazole. Here we report the efficacy [cure rates (CR) and egg-reduction
rates (ERR)], reinfection rates and new infections determined 18 weeks post-treatment.
Results: For a total of 405 children complete baseline and follow-up data were available. Similar to the efficacy
determined after 3 weeks, 18 weeks after treatment albendazole-oxantel pamoate showed a significantly higher
efficacy against T. trichiura (CR: 54.0 %, 95 % CI: 43.7–64.0; ERR: 98.6 %, 95 % CI: 97.8–99.2) compared to the other
treatment arms. Children treated with albendazole-oxantel pamoate or albendazole-ivermectin had fewer
moderate infections compared to children treated with albendazole. The reinfection rates 18 weeks post-treatment
among all treatment arms were 37.2 % for T. trichiura (95 % CI: 28.3–46.8), 34.6 % for A. lumbricoides (95 % CI: 27.3–42.3)
and 25.0 % for hookworms (95 % CI: 15.5–36.6).
Conclusion: The moderate reinfection rates with STHs 18 weeks post-treatment support the concept of regular
anthelminthic treatment in highly endemic settings. Combination chemotherapy might achieve decreased morbidity in
children since in the albendazole plus oxantel pamoate and albendazole plus ivermectin treatment arms only few
moderate T. trichiura infections remained. Further trials should investigate the long term efficacy of albendazole-oxantel
pamoate (i.e. 6 and 12 month post-treatment) and after several rounds of treatment in order to develop
recommendations for appropriate control approaches for STH infections.
Trial registration: Current Controlled Trials ISRCTN80245406
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The most common soil-transmitted helminths (STH; As-
caris lumbricoides, hookworms and Trichuris trichiura)
infect approximately 1.5 billion people [1] worldwide
with the highest prevalences in Asia and Africa. School-
aged children living in the least developed settings, lack-
ing clean water and sanitation facilities are primarily
affected by A. lumbricoides and T. trichiura, while hook-
worm infections mostly occur in adults [2, 3]. Untreated,
chronically infected children might suffer from anemia,
malnutrition and impairments in cognitive and physical
development [2]. The burden of soil-transmitted helminth-
iasis has been estimated as 5.3 million disability-adjusted
life years [1]. Large scale distribution of anthelminthic
drugs without prior diagnosis (“preventive chemotherapy”)
mainly given to school-aged children, is the current strategy
to control morbidity [4]. The most common anthelminthic
drugs are albendazole and mebendazole [5]. Both drugs
have high efficacy against A. lumbricoides, while only alben-
dazole reveals a good performance in the treatment of
hookworm infections. For the treatment of T. trichiura
both drugs show poor cure rates in single-dose regimen [6].
Preventive chemotherapy does not avert reinfections
as demonstrated in earlier studies [7, 8]. Six to 12 months
after treatment with albendazole or mebendazole, the
prevalence of A. lumbricoides reached the pretreatment
level [9–11], while hookworm reinfection is slow [9].
However, it is difficult to accurately estimate the reinfec-
tion rate of T. trichiura since, as mentioned above, the
efficacy of the benzimidazoles against T. trichiura is low
[6], in particular when children suffer from high infec-
tion intensity [12].
In a clinical trial conducted in 2013 on Pemba Island,
Tanzania, we examined the efficacy of three drug
combinations (i.e. albendazole-ivermectin, albendazole-
mebendazole, and albendazole-oxantel pamoate) versus
mebendazole against T. trichiura and concomitant STH
infections [13]. In brief, the combination albendazole-
oxantel pamoate revealed a significantly higher cure rate
(CR) (68.0 %) and egg-reduction rate (ERR 99.2 %) against
T. trichiura than the other treatment regimens. This high
efficacy might allow drawing better conclusions on reinfec-
tion with T. trichiura and ultimately to develop recommen-
dations for control efforts.
The aim of the present study was to investigate
whether the efficacy of albendazole-oxantel pamoate re-
mains superior to the other combinations 18 weeks
post-treatment and to monitor reinfection patterns of T.
trichuris, A. lumbricoides and hookworms.
Methods
Study oversight
The presented data derive from a randomised controlled
trial conducted among school-aged children on PembaIsland, Tanzania [13]. Ethical clearance was obtained
from the Ministry of Health and Social Welfare in Zan-
zibar, Tanzania (ZAMREC, reference no. 0001/June/13)
and from the ethics committee of Basel, Switzerland
(EKBB reference no. 123/13). The trial was registered
with www.isrctn.com (identifier: ISRCTN80245406).
Prior to the study start, written informed consent was
obtained from the parents or legal guardians and verbal
assent from the participating children.
Study procedures and patients
The clinical trial was conducted from September 2013
to January 2014. Study setting and trial procedures are
presented elsewhere [13]. In brief, school-aged children
diagnosed positive for T. trichiura were randomly
assigned to one of the following treatment arms: (i)
albendazole (400 mg) plus ivermectin (200 μg/kg); (ii)
albendazole (400 mg) plus mebendazole (500 mg); (iii)
albendazole (400 mg) plus oxantel pamoate (20 mg/kg);
and (iv) mebendazole (500 mg). All children were invited
3 and 18 weeks after treatment to provide stool samples
on two consecutive days for the diagnosis of STH infec-
tions. Duplicate Kato-Katz thick smears were prepared
from each stool sample using 41.7 mg templates [14]
and quantitatively examined by experienced laboratory
technicians for eggs of T. trichiura, hookworms and
A. lumbricoides. Slides were read under a light micro-
scope within 60 min after preparation to avoid over-
clearing of hookworm eggs [15]. Ten percent of the
Kato-Katz thick smears were randomly chosen and re-
examined to assure high quality of the microscopic diag-
nosis [16]. In case of discrepancies, the slides were read
again and discussed until consensus was reached. At the
end of the study, all children remaining infected from
the two schools (Mchangamdogo and Shungi) received
treatment according to national guidelines [17].
Statistical analysis
Prevalence of infection with T. trichiura, A. lumbricoides
and hookworms was calculated for each treatment arm at
baseline, 3 and 18 weeks post-treatment for all children
with a complete dataset (2 stool samples at each time
point). Differences among treatment arms in CRs 3 weeks
and extended CRs (extended CR: children positive at base-
line and negative at both follow-ups) 18 weeks post-
treatment against T. trichiura, A. lumbricoides and hook-
worms were assessed using logistic regression.
Geometric means (GM) for eggs per gram (EPG) were
calculated by adding 1 to each count (to take the loga-
rithm in case of EPG = 0), taking the GM and subtracting
1 (GM = exp ((∑ log (EPG + 1))/n) − 1) [18]. Bootstrap
resampling method with 10,000 replicates was used for
calculating the 95 % confidence intervals (CI) for the
ERRs. We assumed non-overlapping CI as statistical
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are presented in the Additional file 1: Table S1.
Reinfection rates were defined as children positive at
baseline, negative 3 weeks and positive 18 weeks post-
treatment. New infections were defined as children nega-
tive at baseline and 3 weeks after treatment and positive
18 weeks post-treatment. As all children were by design
positive for T. trichiura, new infections according to our
definition, were only observed for A. lumbricoides and
hookworms. Children negative at baseline and positive
3 weeks later were not included in these calculations
(excluded for A. lumbricoides: 4 out of 405 children; and
for hookworm: 27 out of 405 children).
Results
Efficacy of drug combinations against T. trichiura 3 and
18 weeks post-treatment
In total 405 children infected with T. trichiuria were
allocated to four different treatment regimens andFig. 1 Study design flow chart. Study enrolment, randomisation and two follo
controlled trialprovided all six stool samples (i.e. duplicate stool
samples at baseline, 3 and 18 weeks follow-up; Fig. 1).
The efficacies 3 weeks post-treatment observed with
the different treatment regimens are presented else-
where [13] and summarised in Table 1. The CRs
documented 18 weeks post-treatment were 54.0 %
(43.7–64.0) for albendazole-oxantel pamoate, 20.0 %
(12.7–29.2) for albendazole-ivermectin, 13.9 % (7.8–22.2)
for albendazole-mebendazole and 10.6 % for mebendazole
(5.4–18.1). At the second follow-up, the efficacy of the
other treatment arms remained significantly lower
compared to albendazole-oxantel pamoate in terms of CR
(P-values in Table 1) and ERR (98.6, CI: 97.8–99.2)
compared to the other treatments at the second follow up.
Considering the arithmetic ERRs, albendazole com-
bined with ivermectin and albendazole-oxantel pamo-
ate were significantly higher compared to the other
treatments 18 weeks post-treatment (Additional file 1:
Table S1).w-ups (3 and 18 weeks post-treatment) for the four-arm, randomised
Table 1 Cure rates (CR), extended CRs, egg-reduction rates (ERR), extended ERRs and reinfection data for the four different treatments against T. trichiura infections. Results of
baseline and 3 weeks follow-up have been reported elsewhere [13]
Trichuris trichiura
Weeks post-treatment Albendazole – ivermectin
(n = 100)
Albendazole – mebendazole
(n = 101)
Albendazole – oxantel pamoate
(n = 100)
Mebendazole
(n = 104)
Children positive before
treatment (%)
100 (100) 101 (100) 100 (100) 104 (100)
No. of children cured
(CR, 95 % CI)
3 weeks 28
(28.0, 19.5–37.9, p < 0.001)*
9
(8.9, 4.2–16.2, p < 0.001)*
68 (68.0, 57.9–77.0) 8
(7.7, 3.4–14.6, p < 0.001)*
No. of children negative
(extended CR, 95 % CI)
18 weeks 20
(20.0, 12.7–29.2, p < 0.001)*
14
(13.9, 7.8–22.2, p < 0.001)*
54 (54.0, 43.7–64.0) 11
(10.6, 5.4–18.1, p < 0.001)*
Geometric mean: EPG Baseline 489.9 390.0 471.3 467.8
3 weeks 25.0 176.0 3.7 207.8
18 weeks 47.8 128.1 6.6 158.8
ERR (95 % CI) 3 weeks 94.9 (92.3–96.7) 54.9 (38.3–67.7) 99.2 (98.6–99.6)a 55.6 (40.0–68.0)
Extended ERR (95 % CI) 18 weeks 90.2 (85.3–93.6) 67.2 (51.9–77.9) 98.6 (97.8–99.2)a 66.1 (52.0–76.6)
No. of children positive
(prevalence, 95 % CI)
Baseline 100 (100, −) 101 (100, −) 100 (100, −) 104 (100, −)
3 weeks 72 (72.0, 62.1–80.5) 92 (91.1, 83.8–95.8) 32 (32.0, 23.0–42.1) 96 (92.3, 85.4–96.6)
18 weeks 80 (80.0, 70.8–87.3) 87 (86.1, 77.8–92.2) 46 (46.0, 36.0–56.3) 93 (89.4, 81.9–94.6)
Reinfections (%, 95 % CI) 18 weeks 15/28 (53.6, 33.9–72.5) 2/9 (22.2, 2.8–60.0) 21/68 (30.9, 20.2–43.6) 4/8 (50.0, 15.7–84.3)
Data are n (%, 95 % CI) unless otherwise indicated. EPG = egg per gram of stool. *Significantly lower CR compared to albendazole-oxantel pamoate (P-values derived from logistic regression)
aSignificantly higher ERR compared to other treatment arms (no overlapping confidence interval assumption)
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were equally balanced; 70.9 % of all children harboured
light, 28.6 % moderate and 0.5 % heavy infections, strati-
fied according to The World Health Organisation
(WHO) cut-offs [18]. The number of children with light,
moderate and heavy infection intensities at baseline, 3
and 18 weeks post-treatment for each treatment arm are
summarised in Fig. 2. Albendazole plus ivermectin and
albendazole plus oxantel pamoate caused a higher reduc-
tion of moderate T. trichiura infections 3 and 18 weeks
post-treatment compared to albendazole-mebendazole
and mebendazole. At the 18 weeks follow-up, the number
of moderate infections remained higher for albendazole-
mebendazole (n = 16) and mebendazole (n = 17) unlike
albendazole-ivermectin (n = 2) and albendazole-oxantel
pamoate (n = 3; see Fig. 2).T. trichiura reinfection dynamics
For T. trichiura the prevalence at baseline was 100 % by
design, as only T. trichiura-positive children were in-
cluded (n = 405). In total 42 of 113 children (37.2 %,
28.3–46.8), were reinfected with T. trichiura 18 weeks
after treatment. All reinfections were of mild infection
intensity (Table 1, Fig. 2).Fig. 2 Changes in T. trichiura infection patterns and infection intensities from
treatmentsEfficacy against A. lumbricoides and reinfection dynamics
At baseline, 169 (41.7 %) out of 405 children were in-
fected with A. lumbricoides. All treatment arms achieved
high CRs at the first follow up (Table 2) [13]. CRs de-
creased for all treatment arms 18 weeks post-treatment,
ranging from 60.5 % for mebendazole up to 69.6 % for
albendazole-ivermectin. While at the first follow-up nearly
all eggs were cleared (ERR 99.8–100.0 %), 18 weeks after
treatment the ERRs remained significantly lower (99.0–
99.2 %), except for albendazole-ivermectin (99.7 %).
In total, 57 of the 165 (34.6 %; 27.3–42.3) cured chil-
dren were found to be reinfected 18 weeks after being
treated. Reinfections included light (n = 41) and moderate
(n = 16) infections (Table 2, Fig. 3). In total 58 out of 232
(25.0 %; 19.7–31.1) children had acquired a new light
(n = 50) or moderate (n = 8) A. lumbricoides infection.
Efficacy against hookworms and reinfection dynamics
Hookworm prevalence among the children included in
the trial was 42.5 % (233 of 405 children). At the second
follow-up, slightly higher CRs were observed in all treat-
ment groups compared to 3 weeks post-treatment: 54.0 %
for albendazole-oxantel pamoate, 53.5 % for albendazole-
mebendazole, 50.0 % for albendazole-ivermectin and
34.5 % for mebendazole (Table 3). At this examinationthe baseline to 3 and 18 weeks post-treatment with the four different
Table 2 Cure rates (CR), extended CRs egg-reduction rates (ERR), extended ERRs and reinfection data for the four different
treatments against A. lumbricoides infections. Results of baseline and 3 weeks follow-up have been reported elsewhere [13]
Ascaris lumbricoides
Weeks post-
treatment
Albendazole – ivermectin
(n = 100)
Albendazole – mebendazole
(n = 101)
Albendazole – oxantel
pamoate (n = 100)
Mebendazole
(n = 104)
Children positive before
treatment (%)
46 (46.0) 36 (35.6) 44 (44.0) 43 (41.3)
No. of children cured
(CR, 95 % CI)
3 weeks 45
(97.8, 88.5–99.9)
36
(100, 90.3–100.0)
43
(97.7, 88.0–99.9)
41
(95.4, 84.2–99.4)
No. of children negative
(extended CR, 95 % CI)
18 weeks 32
(69.6, 54.2–82.3)
25
(69.4, 51.9–83.7)
27
(61.4, 45.5–75.6)
26
(60.5, 44.4–75.0)
Geometric mean: EPG Baseline 2,385.8 1,195.3 1,503.4 1,095.2
3 weeks 0.1 0.0 0.2 0.4
18 weeks 6.9 9.1 12.5 10.6
ERR (95 % CI) 3 weeks 99.9
(99.9–100.0)
100 (−) 99.9
(99.9–100)
99.9
(99.8–100)
Extended ERR (95 % CI) 18 weeks 99.7
(99.1–99.9)
99.2
(97.5–99.8)a
99.2
(97.1–99.8)a
99.0
(97.7–99.6)a
No. of children positive
(prevalence, 95 % CI)
Baseline 46
(46.0, 36.1–55.9)
36
(35.6, 26.1–45.1)
44
(44.0, 34.1–53.9)
43
(41.3, 31.7–51.0)
3 weeks 1
(1.0, −1.0–3.0)
2
(2.0, −0.8–4.7)
3
(3.0, −0.4–6.4)
2
(2.0, −0.8–4.6)
18 weeks 24
(24.0, 15.5–32.5)
28
(27.7, 18.8–36.6)
33
(33.0, 23.6–42.4)
33
(31.7, 22.6–40.8)
Reinfections (%, 95 % CI) 18 weeks 14/45
(31.1, 18.2–46.6)
11/36
(30.6, 16.3–48.1)
16/43
(37.2, 23.0–53.3)
16/41
(39.0, 24.2–55.5)
New infections (%, 95 %
CI)
18 weeks 10/54
(18.5, 9.3–31.4)
17/63
(27.0, 16.6–39.7)
15/54
(27.8, 16.5–41.6)
16/61
(26.2, 15.8–39.1)
Data are n (%, 95 % CI) unless otherwise indicated. EPG = egg per gram of stool
aSignificantly lower ERR compared to the 3 weeks ERR (no overlapping confidence interval assumption)
Fig. 3 Changes in A. lumbricoides infection patterns and infection intensities from the baseline to 3 and 18 weeks post-treatment with the four
different treatments
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Table 3 Cure rates (CR), extended CRs, egg-reduction rates (ERR), extended ERRs and reinfection data for the four different
treatments against hookworms infections. Results of baseline and 3 weeks follow-up have been reported elsewhere [13]
Hookworms
Weeks post-
treatment
Albendazole – ivermectin
(n = 100)
Albendazole – mebendazole
(n = 101)
Albendazole – oxantel
pamoate (n = 100)
Mebendazole
(n = 104)
Children positive before
treatment (%)
38 (38.0) 43 (42.6) 50 (50.0) 41 (39.4)
No. of children cured
(CR, 95 % CI)
3 weeks 17
(44.7, 28.6–61.7)
21
(48.8, 33.3–64.5, p = 0.022)*
24
(48.0, 33.7–62.6, p = 0.023)*
10
(24.4, 12.4–40.3)
No. of children negative
(extended CR, 95 % CI)
18 weeks 19
(50.0, 33.4–66.6)
23
(53.5, 37.7–68.8)
27
(54.0, 39.3–68.2)
14
(34.2, 20.1–50.6)
Geometric mean: EPG Baseline 113.1 139.8 87.2 80.0
3 weeks 6.1 8.3 7.1 31.8
18 weeks 6.3 6.3 6.6 20.7
ERR (95 % CI) 3 weeks 94.6
(89.2–97.6)a
94.1
(88.7–97.0)a
91.9
(85.0–95.8)a
60.3
(27.8–79.2)
Extended ERR (95 % CI) 18 weeks 94.4
(88.8–97.5)a
95.5
(91.5–97.8)a
92.4
(85.4–96.3)
74.1
(52.8–86.4)
No. of children positive
(prevalence, 95 % CI)
Baseline 38
(38.0, 28.3–47.7)
43
(42.6, 32.8–52.4)
50
(50.0, 40.0–60.0)
41
(39.4, 29.9–49.0)
3 weeks 26
(26.0, 17.3–34.7)
26
(25.7, 17.1–34.4)
31
(31.0, 21.8–40.2)
44
(42.3, 32.7–52.0)
18 weeks 27
(27.0, 18.1–35.9)
32
(31.7, 22.5–40.9)
34
(34.0, 24.6–43.4)
39
(37.5, 28.0–47.0)
Reinfections
(%, 95 % CI)
18 weeks 5/17
(29.4, 10.3–56.0)
4/21
(19.0, .4–41.9)
6/24
(25.0, 9.8–46.7)
3/10
(30.0, 6.7–65.4)
New infections
(%, 95 % CI)
18 weeks 6/57
(10.5, 4.0–21.5)
9/54
(16.7, 7.9–29.3)
8/45
(17.8, 8.0–32.1)
6/50
(12.0, 4.5–24.3)
Data are n (%, 95 % CI) unless otherwise indicated. EPG = egg per gram of stool
*Significantly higher CR compared to mebendazole (P-values derived from logistic regression)
aSignificantly higher ERR compared to mebendazole (no overlapping confidence interval assumption)
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albendazole-mebendazole (95.5 %; 91.5–97.8), achieved
significantly higher ERRs in comparison to mebendazole
(74.1 %; 52.8–86.4). The arithmetic ERRs showed compar-
able results (Additional file 1: Table S1).
Eighteen weeks post-treatment 18 out of 72 (25.0 %;
15.5–36.6) children were reinfected with hookworms.
All infections were of mild intensity (Table 3, Fig. 4). In
total, 29 out of 206 children (14.1 %, CI 9.6–19.6) had ac-
quired a new infection, ranging from 10.5 % (albendazole-
ivermectin) to 17.8 % (albendazole-oxantel pamoate).
Discussion
In preventive chemotherapy control programs albenda-
zole and mebendazole are the treatment of choice
against infections with all three STHs, yet both reveal a
poor efficacy against T. trichiura [6]. In the recent past,
oxantel pamoate has emerged as frontrunner for the
treatment of infections with T. trichiura [13, 19, 20]. In
more detail, in our recent studies albendazole-oxantel
pamoate revealed good CRs and high ERRs, while
mebendazole achieved CRs of 11.8 % [19] and 8.4 % [13]
against T. trichiura infection. This low efficacy ofmebendazole in the Pemba setting might be due to the
occurrence of drug resistance, although molecular stud-
ies were not carried out to demonstrate it. In this sce-
nario that is common also to other STH endemic areas,
the need of new drug combinations in order to expand
the armamentarium of treatments available for prevent-
ive chemotherapy strategy is of utmost importance [21].
In addition, albendazole-oxantel pamoate achieved a high
reduction of moderate T. trichiura infections (persisting at
18 weeks post-treatment) in contrast to mebendazole. Note
that, the goal of preventive chemotherapy is to reduce the
morbidity from STH in pre- and school-aged children, by
decreasing moderate and heavy infection intensities to a
level below 1 % [22]. The combination albendazole-oxantel
pamoate might contribute to achieve this goal.
Infections after treatment re-appear fast, particularly
for A. lumbricoides and hence have a huge impact on
the success of preventive chemotherapy [9]. This study
presents detailed insights about the impact of drug com-
binations including the effective oxantel pamoate com-
bination on the reinfection dynamics of the three STHs
in a highly endemic area on Pemba Island, Tanzania.
Earlier studies on reinfection struggled with the low CR
Fig. 4 Changes in hookworms infection patterns and infection intensities from the baseline to 3 and 18 weeks post-treatment with the four
different treatments
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cated drawing sound conclusions against this helminth
species [9, 23].
Previous studies on reinfection mainly described the re-
acquired level of infection after treatment, in comparison
to the pre-treatment level and presented the prevalence
risk ratio [9, 24, 25]. With the focus only on prevalence
before and after treatment, new infections are falsely con-
sidered as reinfection. Furthermore, prevalence risk ratios
are strongly influenced by the achieved CRs of the treat-
ments. Hence, in this study we distinguish and present
both; reinfections rates (positive children at baseline,
negative at the 3 week examination point and positive
18 weeks after treatment) and new infections (children
with an infection exclusively 18 weeks post-treatment).
Note that, children negative at baseline and positive
3 weeks later, which was observed for A. lumbricoides and
hookworms, were not considered as new infections. We
assume, that these children either harboured a non-patent
infection or were wrongly diagnosed as negative at base-
line [26]. We are confident that our differentiation be-
tween reinfections and new infections holds true given
that the majority of A. lumbricoides and hookworminfections were of moderate intensities at baseline. How-
ever, obviously the low sensitivity of the Kato-Katz tech-
nique mainly for light infection intensities [26–28] reflects
a general limitation of our study. Please note that in the
present study four slides were examined by Kato-Katz.
However, even when examining multiple thick smears the
Kato-Katz method only reaches moderate sensitivity [29].
Therefore our results (i.e. re-infection, new infection) have
to be interpreted with caution.
Earlier studies on reinfection with T. trichiura re-
ported prevalence to pre-treatment level between 6 and
12 months [9–11, 24, 30]. In our study, the overall re-
infection rate 18 weeks post-treatment for T. trichiura
was 37.2 %, which is comparable to the 3 month post
treatment prevalence risk ratio of 36.0 % reported by
Sinniah [31] and 39.7 % by Al-Mekhlafi et al. [24]. A
similar reinfection rate was observed for A. lumbricoides
(34.6 %), which is in agreement with the 3 month post-
treatment data of Jia et al. [9]. On the other hand, Yap
et al. [30] documented a higher reinfection rate 4 months
after treatment. Additionally, 58 (25 %) of the children
negative at baseline acquired a new A. lumbricoides infec-
tion 18 weeks post-treatment. Interestingly, 24 children
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harboured already a moderate infection 18 weeks post-
treatment, indicating the fast reinfection potential of
A. lumbricoides [22].
The three drug combinations cured nearly half of the
hookworm-infected children 3 weeks post-treatment, while
as expected mebendazole achieved only low CRs [32–35].
Surprisingly, the extended CRs and ERRs among all treat-
ment arms (except the ERR from albendazole-ivermectin)
increased at the second compared to the first follow-up.
For example, in the mebendazole group, 14 children iden-
tified as hookworm-positive 3 weeks post-treatment were
negative at the second follow up. This finding is most
likely due to a diagnostic issue, i.e. the low sensitivity of
Kato-Katz for low egg-counts [36] and a delayed reading
of the microscope slides [15, 37], which could have led to
fluctuations of Kato-Katz results. Overall, the reinfection
rate was slower and less new infections with hookworms
were observed compared to A. lumbricoides and T.
trichiura, which is in agreement with other studies [9].
Conclusions
In conclusion, our study has reconfirmed the excellent
efficacy of an albendazole-oxantel pamoate combination
against T. trichiura infections. This combination could
become a key element in controlling STH infections,
especially in highly endemic settings. Further trials,
should evaluate reinfection rates with oxantel pamoate
six and 12 month after treatment and ideally after
several rounds of treatment.
The moderate reinfection rate observed for T. trichiura
and A. lumbricoides is worrying. This finding supports the
necessity of an integrated control approaches including
regular treatment, improved sanitation and health educa-
tion [38–41], in order to reduce the burden of STH
infections.
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